Analysts think INCY stock price could increase by 21%
May 05, 2025, 11:25 AM
7.39%
What does INCY do
Yte is a Wilmington, Delaware-based biopharmaceutical company with 2,524 employees, focusing on hematology/oncology and inflammation/autoimmunity therapeutic areas. Its product portfolio includes JAKAFI, MONJUVI, and PEMAZYRE, among others.
24 analysts think INCY stock price will increase by 20.74%. The current median analyst target is $75.48 compared to a current stock price of $62.52. The lowest analysts target is $52.52 and the highest analyst target is $96.60.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.